Overcoming DLBCL Treatment Hurdles

Experts discuss limitations and operational strategies for integrating bispecifics in DLBCL (diffuse large B cell lymphoma) treatment; addressing side effects, education, clinical pathways, and collaboration for effective patient care.

Related Keywords

,Emerging Role ,Bispecific Antibodies ,Diffuse Largeb Cell Lymphoma Management ,Dlbcl ,Clinical Trials ,Epcorinomab ,Glofitomab ,Approval ,Response Rates ,Duration Of Response ,Progression Free Survival ,Toxicity Profiles ,Crs ,Neurotoxicity ,Trial Design ,Patient Cohorts ,